ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2646

Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record

Wenlu Xiong1, J.B. Boone1, Cecilia P. Chung1, Leslie Crofford2 and April Barnado2, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antimalarial drugs, Nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data showed AMs are not universally prescribed. Using a real-world electronic health record (EHR) cohort, SLE nephritis vs. non-nephritis patients were less likely to be prescribed AMs. We examined if patient or prescriber characteristics impact AM prescribing patterns.

Methods: Potential SLE cases were from a de-identified EHR with 2.8 million subjects using a previously validated algorithm of 4 or more counts of the SLE ICD-9 code (710.0) and antinuclear antibody (ANA) positive (titer ≥ 1:160) while excluding dermatomyositis and systemic sclerosis ICD-9 codes. A subject was a case if diagnosed with SLE by a specialist (rheumatologist or nephrologist). SLE nephritis was defined as positive renal biopsy or clinical diagnosis by a specialist. We assessed for current use of AMs as documented by a specialist’s note closest to October 1, 2015 (end of ICD-9 coding). We collected age at time of analysis, sex, race/ethnicity, specialist prescribing AM, and whether patients underwent dialysis or kidney transplant. The kidney function and blood counts closest to the specialist’s note date were recorded. We evaluated for differences in SLE cases currently prescribed AMs vs. those not using the Mann-Whitney U test for continuous variables and chi-square or Fisher’s exact test for categorical variables.

Results: Our validated algorithm identified 1147 potential SLE subjects with 977 chart-confirmed SLE cases and 244 SLE nephritis cases. Of the SLE nephritis cases, mean age was 43 ± 16 years with 89% female, 47% Caucasian, 44% African American, 6% Asian, and 3% Hispanic. Among cases, 81% were followed by a rheumatologist with 38% ever on dialysis and 21% receiving kidney transplant. Only 63% (n = 153) of SLE nephritis cases were current AM users. No retinopathy was noted in cases not prescribed AMs. There were no differences in sex or race between current vs. non-current users (Table 1). Current users were significantly younger than non-current users (p < 0.001). Patients were more likely to be prescribed AMs when followed by a rheumatologist vs. a nephrologist (76% vs. 37%, p < 0.001). Current vs. non-current users were less likely to be on dialysis (p < 0.001) and less likely to have had a kidney transplant (p < 0.001). Current vs. non-current users had significantly lower creatinine (p < 0.001), lower urine protein/creatinine ratio (p = 0.04), and higher hemoglobin (p < 0.01).

Conclusion: Using a large EHR cohort, only 63% of SLE nephritis cases are currently prescribed AMs. As AMs reduce renal damage in SLE nephritis, our results demonstrate an opportunity to target future efforts to improving adherence to guidelines for AM prescribing.

Table 1.

SLE nephritis cases

(n = 244)

Currently

Prescribed Antimalarials

(n = 153)

Not Currently Prescribed Antimalarials

(n = 88)

p valuea

Current age,

mean ± SD (years)

39 ± 14

50 ± 17

< 0.001

Sex, n (%)

Female

Male

134 (63%)

19 (68%)

79 (37%)

9 (32%)

0.68

 

Race/ethnicity, n (%)

Caucasian

African American

Hispanic

Asian

73 (66%)

60 (59%)

5 (63%)

11 (79%)

37 (34%)

42 (41%)

3 (37%)

3 (21%)

0.46

Prescribing specialistb, n (%)

Rheumatology

Nephrology

Both

142 (76%)

10 (37%)

0 (0%)

46 (24%)

17 (63%)

14 (100%)

< 0.001

Dialysis, n (%)

35 (38%)

56 (62%)

< 0.001

Renal transplant, n (%)

13 (26%)

37 (74%)

< 0.001

Serum creatinine, mean ± SD

1.8 ± 2.7

3.0 ± 3.2

< 0.001

Urine protein/creatinine ratio, mean ± SD

1.4 ± 2.6

3.0 ± 6.3

0.04

WBC count, mean ± SD

7.4 ± 5.4

8.0 ± 4.9

0.07

Hemoglobin, mean ± SD

12.1 ± 2.1

11.2 ± 2.3

< 0.01

Platelet count, mean ± SD

240 ± 91

224 ± 93

0.23

aChi-square, Fisher’s exact test, or Mann-Whitney U test

bBoth indicates followed by rheumatologist and nephrologist

 


Disclosure: W. Xiong, None; J. B. Boone, None; C. P. Chung, None; L. Crofford, None; A. Barnado, None.

To cite this abstract in AMA style:

Xiong W, Boone JB, Chung CP, Crofford L, Barnado A. Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/disparities-in-antimalarial-prescribing-for-systemic-lupus-erythematous-nephritis-using-a-real-world-electronic-health-record/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disparities-in-antimalarial-prescribing-for-systemic-lupus-erythematous-nephritis-using-a-real-world-electronic-health-record/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences